The application, No. 20060058266, is entitled "Chemically modified oligonucleotides," and claims "composition and methods for making and using chemically modified oligonucleotide agents for inhibiting gene expression," according to its abstract.
Marketing director Dalsoo Kim said the company now sells a PANArray miRNA expression-profiling kit for surveying stem cell-related miRNAs. The launch follows its debut in June of a kit for profiling cancer-related miRNAs.
In the advance online version of Nucleic Acids Research, Santaris investigators reported data identifying miR-155, an miRNA involved in immune-system regulation, as a possible therapeutic target for chronic inflammatory diseases such as rheumatoid arthritis.
The release of the data comes on the heels of a publication in Cell showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, which Mirna's CEO said bolsters the company's strategy.